Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting, 12483-12484 [2021-04371]
Download as PDF
Federal Register / Vol. 86, No. 40 / Wednesday, March 3, 2021 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
Lane, Rm. 1061, Rockville, MD 20852,
240–402–7500, or at https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Jaime Espinosa, (ELEM–4029) Division
of Enforcement, Office of Strategic
Planning and Operational Policy, Office
of Regulatory Affairs, Food and Drug
Administration, 12420 Parklawn Dr.,
Rockville, MD 20857, 240–402–8743, or
at debarments@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(a)(2)(B) of the FD&C Act
(21 U.S.C. 335a(a)(2)(B)) requires
debarment of an individual from
providing services in any capacity to a
person that has an approved or pending
drug product application if FDA finds
that the individual has been convicted
of a felony under Federal law for
conduct relating to the regulation of any
drug product under the FD&C Act. On
June 18, 2020, Mr. Ryan was convicted
as defined in section 306(l)(1) of the
FD&C Act when judgment was entered
against him in the U.S. District Court for
the Eastern District of Virginia, Norfolk
Division, after his plea of guilty to one
count of conspiracy to defraud the
United States in violation of 18 U.S.C.
371.
The factual basis for this conviction is
as follows: As contained in the
Statement of Facts in Mr. Ryan’s case,
filed on January 8, 2020, from October
2007, and continuing through
September 2010, Mr. Ryan, a physician,
authorized drug orders for RX Limited
(also known as RX Partners), an internet
pharmacy organization that facilitated
the unlawful distribution of prescription
drugs to consumers throughout the
United States. RX Limited had a
business model whereby it allowed
consumers to fill out a brief medical
questionnaire, select the type of drugs
the consumer desired, the desired drug
strength, and the desired drug quantity
and pay by credit card. RX Limited then
forwarded the order to a participating
physician for ‘‘approval.’’ The drugs
sold by RX Limited were dispensed
without a valid prescription because
there was no valid doctor-patient
relationship established between the
authorizing physicians and the
customers. Customers had no face-toface contact with the participating
physician and were not subject to any
mental or physical examinations.
The physicians authorizing the orders
for prescription drugs sold by RX
Limited did not take patient histories or
perform any diagnostic or laboratory
testing, did not check the accuracy of
the information customers provided
VerDate Sep<11>2014
17:29 Mar 02, 2021
Jkt 253001
(including their identities, ages, and
qualifying medical conditions), and did
not monitor, or provide any means to
monitor, medication response. After the
participating physician authorized the
prescription, RX Limited sent the order
to a fulfillment pharmacy, which
fulfilled the order and mailed the drugs
to the customer.
As a participating physician, Mr.
Ryan authorized more than 158,000
drug orders for well over 10 individual
RX Limited customers. Prescription
drugs distributed pursuant to these
orders included, FIORICET (and its
generic equivalents), Carisoprodol
(SOMA), Tramadol (ULTRAM),
VIAGRA, CIALIS, and XENICAL. RX
Limited paid Mr. Ryan $2.00 per drug
order he authorized. From October 2007
through September 2010, RX Limited
paid Mr. Ryan at least $316,153 for the
orders he authorized.
As a result of this conviction, FDA
sent Mr. Ryan by certified mail on
September 11, 2020, a notice proposing
to permanently debar him from
providing services in any capacity to a
person that has an approved or pending
drug product application. The proposal
was based on a finding, under section
306(a)(2)(B) of the FD&C Act, that Mr.
Ryan was convicted of a felony under
Federal law for conduct relating to the
regulation of a drug product under the
FD&C Act. The proposal also offered Mr.
Ryan an opportunity to request a
hearing, providing him 30 days from the
date of receipt of the letter in which to
file the request, and advised him that
failure to request a hearing constituted
an election not to use the opportunity
for a hearing and a waiver of any
contentions concerning this action. Mr.
Ryan received the proposal on
September 18, 2020. Mr. Ryan did not
request a hearing within the timeframe
prescribed by regulation and has,
therefore, waived his opportunity for a
hearing and any contentions concerning
his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant
Commissioner, Office of Human and
Animal Food Operations, under section
306(a)(2)(B) of the FD&C Act, under
authority delegated to the Assistant
Commissioner, finds that Mr. Ryan, has
been convicted of a felony under
Federal law for conduct otherwise
relating to the regulation of a drug
product under the FD&C Act.
As a result of the foregoing finding,
Mr. Ryan, is permanently debarred from
providing services in any capacity to a
person with an approved or pending
drug product application, effective (see
DATES) (see sections 306(a)(2)(B) and
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
12483
(c)(2)(A)(ii) of the FD&C Act). Any
person with an approved or pending
drug product application who
knowingly employs or retains as a
consultant or contractor, or otherwise
uses the services of, Mr. Ryan, in any
capacity during his debarment, will be
subject to civil money penalties (section
307(a)(6) of the FD&C Act (21 U.S.C.
335b(a)(6))). If Mr. Ryan provides
services in any capacity to a person with
an approved or pending drug product
application during his period of
debarment, he will be subject to civil
money penalties (section 307(a)(7) of the
FD&C Act). In addition, FDA will not
accept or review any abbreviated new
drug application from Mr. Ryan during
his period of debarment, other than in
connection with an audit under section
306 of the FD&C Act (section
306(c)(1)(B)). Note that, for purposes of
section 306 of the FD&C Act, a ‘‘drug
product’’ is defined as a drug subject to
regulation under section 505, 512, or
802 of the FD&C Act (21 U.S.C. 355,
360b, or 382) or under section 351 of the
Public Health Service Act (42 U.S.C.
262) (see section 201(dd) of the FD&C
Act (21 U.S.C. 321(dd))).
Any application by Mr. Ryan for
special termination of debarment under
section 306(d)(4) of the FD&C Act
should be identified with Docket No.
FDA–2020–N–1638 and sent to the
Dockets Management Staff (see
ADDRESSES). The public availability of
information in these submissions is
governed by 21 CFR 10.20.
Publicly available submissions will be
placed in the docket and will be
viewable at https://www.regulations.gov
or at the Dockets Management Staff (see
ADDRESSES) between 9 a.m. and 4 p.m.,
Monday through Friday, 240–402–7500.
Dated: February 25, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–04375 Filed 3–2–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0008]
Circulatory System Devices Panel of
the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
SUMMARY:
E:\FR\FM\03MRN1.SGM
03MRN1
12484
Federal Register / Vol. 86, No. 40 / Wednesday, March 3, 2021 / Notices
forthcoming public advisory committee
meeting of the Circulatory System
Devices Panel of the Medical Devices
Advisory Committee. The general
function of the committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public.
DATES: The meeting will take place
virtually on April 6, 2021, from 9 a.m.
Eastern Time to 6 p.m. Eastern Time.
ADDRESSES: Please note that due to the
impact of this COVID–19 pandemic, all
meeting participants will be joining this
advisory committee meeting via an
online teleconferencing platform.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability may
be accessed at: https://www.fda.gov/
advisory-committees/about-advisorycommittees/common-questions-andanswers-about-fda-advisory-committeemeetings.
jbell on DSKJLSW7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Aden Asefa, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5214, Silver Spring,
MD 20993–0002, aden.asefa@
fda.hhs.gov, 301–796–0400, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing platform. On April 6,
2021, the committee will discuss, make
recommendations, and vote on
information regarding the premarket
approval application for the
TransMedics Organ Care System (OCS)
Heart, by TransMedics, Inc. The
proposed Indication for Use for the
TransMedics OCS Heart, is as follows:
The TransMedics Organ Care System
(OCS) Heart System is a portable
extracorporeal heart perfusion and
monitoring system indicated for the
resuscitation, preservation, and
assessment of donor hearts in a nearphysiologic, normothermic, and beating
VerDate Sep<11>2014
17:29 Mar 02, 2021
Jkt 253001
state intended for a potential transplant
recipient.
OCS Heart is indicated for donor
hearts with one or more of the following
characteristics:
• Expected cross-clamp or ischemic
time ≥4 hours due to donor or
recipient characteristics (e.g.,
donor- recipient geographical
distance, expected recipient
surgical time); or
• Expected total cross-clamp time of
≥2 hours PLUS one of the following risk
factors:
• Donor Age ≥55 years; or
• Donors with history of cardiac
arrest and downtime ≥20 minutes; or
• Donor history of alcoholism; or
• Donor history of diabetes; or
• Donor Left Ventricular Ejection
Fraction ≤50 percent but ≥40 percent; or
• Donor history of Left Ventricular
Hypertrophy (septal or posterior wall
thickness of >12 and ≤16 mm); or
• Donor angiogram with luminal
irregularities but no significant coronary
artery disease.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available on FDA’s
website at the time of the advisory
committee meeting, and the background
material will be posted on FDA’s
website after the meeting. Background
material and the link to the online
teleconference meeting room will be
available at https://www.fda.gov/
advisory-committees/circulatory-systemdevices-panel/2021-meeting-materialscirculatory-system-devices-panel. Select
the link for the 2021 Meeting Materials.
The meeting will include slide
presentations with audio components to
allow the presentation of materials in a
manner that most closely resembles an
in-person advisory committee meeting.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before March 30, 2021.
Oral presentations from the public will
be scheduled on April 6, 2021, between
approximately 1 p.m. Eastern Time and
2 p.m. Eastern Time. Those individuals
interested in making formal oral
presentations should notify the contact
person (see FOR FURTHER INFORMATION
CONTACT). The notification should
include a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
an indication of the approximate time
requested to make their presentation on
or before March 22, 2021. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 23, 2021.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Artair Mallet
at Artair.Mallet@fda.hhs.gov or 301–
796–9638 at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/advisorycommittees/about-advisory-committees/
public-conduct-during-fda-advisorycommittee-meetings for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: February 25, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–04371 Filed 3–2–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–N–1411]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Generic Clearance
for Data To Support Cross-Center
Collaboration for Social Behavioral
Sciences Associated With Disease
Prevention, Treatment, and the Safety,
Efficacy, and Usage of Food and Drug
Administration Regulated Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing that a proposed collection
SUMMARY:
E:\FR\FM\03MRN1.SGM
03MRN1
Agencies
[Federal Register Volume 86, Number 40 (Wednesday, March 3, 2021)]
[Notices]
[Pages 12483-12484]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04371]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0008]
Circulatory System Devices Panel of the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a
[[Page 12484]]
forthcoming public advisory committee meeting of the Circulatory System
Devices Panel of the Medical Devices Advisory Committee. The general
function of the committee is to provide advice and recommendations to
the Agency on FDA's regulatory issues. The meeting will be open to the
public.
DATES: The meeting will take place virtually on April 6, 2021, from 9
a.m. Eastern Time to 6 p.m. Eastern Time.
ADDRESSES: Please note that due to the impact of this COVID-19
pandemic, all meeting participants will be joining this advisory
committee meeting via an online teleconferencing platform. Answers to
commonly asked questions including information regarding special
accommodations due to a disability may be accessed at: https://www.fda.gov/advisory-committees/about-advisory-committees/common-questions-and-answers-about-fda-advisory-committee-meetings.
FOR FURTHER INFORMATION CONTACT: Aden Asefa, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5214, Silver Spring, MD 20993-0002,
[email protected], 301-796-0400, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). A notice in the Federal Register about last minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. On April 6,
2021, the committee will discuss, make recommendations, and vote on
information regarding the premarket approval application for the
TransMedics Organ Care System (OCS) Heart, by TransMedics, Inc. The
proposed Indication for Use for the TransMedics OCS Heart, is as
follows: The TransMedics Organ Care System (OCS) Heart System is a
portable extracorporeal heart perfusion and monitoring system indicated
for the resuscitation, preservation, and assessment of donor hearts in
a near-physiologic, normothermic, and beating state intended for a
potential transplant recipient.
OCS Heart is indicated for donor hearts with one or more of the
following characteristics:
Expected cross-clamp or ischemic time >=4 hours due to donor
or recipient characteristics (e.g., donor- recipient geographical
distance, expected recipient surgical time); or
Expected total cross-clamp time of >=2 hours PLUS one of
the following risk factors:
Donor Age >=55 years; or
Donors with history of cardiac arrest and downtime >=20
minutes; or
Donor history of alcoholism; or
Donor history of diabetes; or
Donor Left Ventricular Ejection Fraction <=50 percent but
>=40 percent; or
Donor history of Left Ventricular Hypertrophy (septal or
posterior wall thickness of >12 and <=16 mm); or
Donor angiogram with luminal irregularities but no
significant coronary artery disease.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will be made publicly available on FDA's website at
the time of the advisory committee meeting, and the background material
will be posted on FDA's website after the meeting. Background material
and the link to the online teleconference meeting room will be
available at https://www.fda.gov/advisory-committees/circulatory-system-devices-panel/2021-meeting-materials-circulatory-system-devices-panel. Select the link for the 2021 Meeting Materials. The meeting will
include slide presentations with audio components to allow the
presentation of materials in a manner that most closely resembles an
in-person advisory committee meeting.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
March 30, 2021. Oral presentations from the public will be scheduled on
April 6, 2021, between approximately 1 p.m. Eastern Time and 2 p.m.
Eastern Time. Those individuals interested in making formal oral
presentations should notify the contact person (see FOR FURTHER
INFORMATION CONTACT). The notification should include a brief statement
of the general nature of the evidence or arguments they wish to
present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their presentation
on or before March 22, 2021. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by March 23,
2021.
For press inquiries, please contact the Office of Media Affairs at
[email protected] or 301-796-4540.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Artair Mallet at [email protected] or 301-796-9638 at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/advisory-committees/about-advisory-committees/public-conduct-during-fda-advisory-committee-meetings for procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: February 25, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-04371 Filed 3-2-21; 8:45 am]
BILLING CODE 4164-01-P